14.71
price down icon12.23%   -2.05
pre-market  Pre-mercato:  14.80   0.09   +0.61%
loading

Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie

pulisher
12:15 PM

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results - BioSpace

12:15 PM
pulisher
Jul 21, 2025

What drives Arrowhead Pharmaceuticals Inc. stock priceFree Stock Market Return Analysis - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

What analysts say about Arrowhead Pharmaceuticals Inc. stockExceptional profit velocity - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

Arrowhead hits the skids due to partnership with Sarepta - Seeking Alpha

Jul 21, 2025
pulisher
Jul 21, 2025

Arrowhead Pharmaceuticals Plummets 9.4%: A Bearish Surprise in Biotech's RNAi Frontier - AInvest

Jul 21, 2025
pulisher
Jul 20, 2025

Arrowhead Pharmaceuticals Inc. Stock Analysis and ForecastPowerful market insights - Autocar Professional

Jul 20, 2025
pulisher
Jul 19, 2025

Is Arrowhead Pharmaceuticals Inc. a good long term investmentExceptional growth trajectory - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

Insiders At Arrowhead Pharmaceuticals Sold US$3.1m In Stock, Alluding To Potential Weakness - simplywall.st

Jul 18, 2025
pulisher
Jul 10, 2025

Arrowhead Pharmaceuticals Advances Phase 3 Study on Plozasiran for Hypertriglyceridemia - TipRanks

Jul 10, 2025
pulisher
Jul 09, 2025

Arrowhead Pharmaceuticals (ARWR) Soars 7.64% on Clinical Trial Advances - AInvest

Jul 09, 2025
pulisher
Jul 09, 2025

Arrowhead Pharmaceuticals Advances Phase 3 Study of Zodasiran for Cholesterol Management - TipRanks

Jul 09, 2025
pulisher
Jul 08, 2025

Arrowhead Pharmaceuticals' Zodasiran: A Pioneering ANGPTL3 Inhibitor for HoFH and Beyond - AInvest

Jul 08, 2025
pulisher
Jul 08, 2025

Arrowhead Pharmaceuticals initiates phase 3 Yosemite study of investigational zodasiran - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia - Business Wire

Jul 08, 2025
pulisher
Jun 25, 2025

Hepatitis D Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Eiger Biopharmaceuticals, Arrowhead Pharmaceuticals, Antios Therapeutics, PharmaEsse - The Globe and Mail

Jun 25, 2025
pulisher
Jun 23, 2025

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran - Business Wire

Jun 23, 2025
pulisher
Jun 12, 2025

Where are the Opportunities in (ARWR) - news.stocktradersdaily.com

Jun 12, 2025
pulisher
Jun 12, 2025

Homozygous Familial Hypercholesterolemia Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Arrowhead Pharma, Novartis, Alnylam Pharma, LIB Therapeutics, Amryt Pharma - The Globe and Mail

Jun 12, 2025
pulisher
Jun 12, 2025

GAMMA Investing LLC Increases Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Cantor Fitzgerald Weighs in on ARWR FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 10, 2025

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Arrowhead Pharmaceuticals at Goldman Sachs Conference: Strategic Launch Plans By Investing.com - Investing.com Canada

Jun 09, 2025
pulisher
Jun 08, 2025

California State Teachers Retirement System Reduces Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded to “Buy” at Wall Street Zen - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money” - Insider Monkey

Jun 05, 2025
pulisher
Jun 04, 2025

Arrowhead at Jefferies Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada

Jun 04, 2025
pulisher
Jun 04, 2025

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses' - Benzinga

Jun 04, 2025
pulisher
Jun 04, 2025

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences - Business Wire

Jun 04, 2025
pulisher
Jun 02, 2025

Arrowhead (ARWR) Kicks Off Clinical Trial for Obesity Treatment ARO-ALK7 | ARWR Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Arrowhead Pharmaceuticals, Inc. (ARWR)’s ARO-ALK7 Enters Phase 1/2a Study - Insider Monkey

Jun 02, 2025
pulisher
Jun 02, 2025

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity - BioSpace

Jun 02, 2025
pulisher
Jun 02, 2025

Arrowhead Pharmaceuticals Initiates Phase 1/2A Study Of Aro-Alk7 For The Treatment Of Obesity - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity | ARWR Stock News - GuruFocus

Jun 02, 2025
pulisher
May 31, 2025

(ARWR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

May 31, 2025
pulisher
May 30, 2025

SA analyst downgrades: PLTR, PSTG, NTLA, ARWR - Seeking Alpha

May 30, 2025
pulisher
May 29, 2025

Arrowhead Pharmaceuticals: A Reluctant Sell Rating Explained (Rating Downgrade) (ARWR) - Seeking Alpha

May 29, 2025
pulisher
May 29, 2025

Arrowhead Pharmaceuticals to Participate in June 2025 Investor C - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Arrowhead (ARWR) Skyrockets Over 5.7%: Can This Biotech Breakout Propel It Towards $20? - Daily Chhattisgarh News

May 29, 2025
pulisher
May 24, 2025

Arrowhead Pharmaceuticals’ SWOT analysis: RNAi pioneer nears first approval - Investing.com

May 24, 2025
pulisher
May 23, 2025

What is HC Wainwright’s Estimate for ARWR FY2025 Earnings? - Defense World

May 23, 2025
pulisher
May 22, 2025

HC Wainwright Reiterates Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - Defense World

May 22, 2025
pulisher
May 21, 2025

Arrowhead at RBC Conference: Strategic Insights on Drug Pipeline By Investing.com - Investing.com India

May 21, 2025
pulisher
May 20, 2025

Arrowhead Pharma (ARWR) Receives Reiterated Buy Rating from HC Wainwright | ARWR Stock News - GuruFocus

May 20, 2025
pulisher
May 19, 2025

BNP Paribas Financial Markets Acquires 32,841 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

May 19, 2025
pulisher
May 18, 2025

Research Analysts Offer Predictions for ARWR FY2025 Earnings - Defense World

May 18, 2025
pulisher
May 18, 2025

B. Riley Brokers Boost Earnings Estimates for ARWR - Defense World

May 18, 2025
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
Capitalizzazione:     |  Volume (24 ore):